Kessler Topaz Meltzer & Check, LLP: Investor Class Action Filed Against Teladoc Health, Inc. for Securities Fraud Violations

Notice is hereby given that a class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Teladoc Health, Inc. (“Teladoc”) (NYSE: TDOC) securities between March 3, 2016, and December 5, 2018, both dates inclusive (the “Class Period”).

Teladoc investors may receive additional information about the case by clicking the link "Submit Your Information" above.

According to the complaint, Teladoc was formerly known as “Teladoc, Inc.” and changed its name to “Teladoc Health, Inc.” in August 2018.  Teladoc provides telehealth services worldwide and offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. Teladoc provides its services through mobile devices, the Internet, video, and phone.

The Class Period commences on March 3, 2016, when Teladoc filed its Form 10-K for the fiscal year ended December 31, 2015.  The Form 10-K stated, in relevant part, “[w]e depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.”

According to the complaint, the Southern Investigative Research Foundation (“SIRF”) published an article reporting that Teladoc had allowed violations of employment discrimination laws, sexual harassment laws, and its own corporate governance policies to take place at the company for years.  Specifically, the article alleged that Mark Hirschhorn (“Hirschhorn”), the Executive Vice President (“EVP”), Chief Operating Officer (“COO”), and Chief Financial Officer (“CFO”) of Teladoc, had engaged in an affair with a low-level employee of Teladoc in Texas named Charece Griffin (“Griffin”), and that the two engaged in potentially illegal insider trading. The SIRF article cited a thorough investigation of the foregoing issues, which included interviews with at least seven former colleagues of Griffin between 2014 and the end of 2017.

Following publication of the SIRF article, Teladoc’s stock price fell $4.00, or 6.69%, to close at $55.81 on December 6, 2018.

The complaint alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) Hirschhorn was engaged in an inappropriate sexual relationship with a subordinate; (ii) Hirschhorn and this subordinate engaged in insider trading to provide themselves with undue benefits; (iii) Hirschhorn caused the subordinate to receive promotions for which she was unqualified, thereby negatively impacting Teladoc’s operations; (iv) Teladoc’s enforcement of its own purported employment and trading policies were inadequate to prevent the foregoing conduct; and (v) as a result, Teladoc’s public statements were materially false and misleading at all relevant times.

If you are a member of the class described above, you may no later than February 11, 2019 move the Court to serve as lead plaintiff of the class, if you so choose.

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of their choice, or may choose to do nothing and remain an inactive class member.

Kessler Topaz Meltzer & Check, LLP has not filed a complaint in this matter.  If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at

Please complete this form relating to your transactions for Teladoc Health, Inc. (NYSE: TDOC) securities between March 3, 2016, and December 5, 2018, both dates inclusive (the “Class Period”). 

Once completed, please click the orange “Submit Your Information” button at the bottom of this page. You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 888.299.7706, or you may submit your information via email at

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Teladoc Health, Inc. prior to the Class Period?
Are you a current or former employee of Teladoc Health, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
I would like to receive
new case alerts by email